Positions

Overview

  • Dr. Manne obtained his M.S. (Biochemistry, Histochemistry, Parasitology, Zoonosis) and Ph.D. (energy metabolic pathways of endoparasites) degrees from Osmania University, Hyderabad, India. His postdoctoral training was in molecular immunology and vaccine development for malaria (Malaria Research Center, Delhi, India); in helicobacter infections (School of Microbiology, University of New South Wales, Sydney, Australia); and in histopathology, molecular tumor biology, and preclinical translational research of human malignancies at the University of Alabama at Birmingham (UAB). He also received certification in bioinformatics at UAB. Dr. Manne’s research on racial disparity in CRC has received considerable national and international recognition. In 2009, the Presidents Cancer Panel invited Dr. Manne to speak on “Biologic differences between ethnic groups and their clinical implications in cancer care,” and devoted to the topic, “America’s demographic and cultural transformation: implications for the cancer enterprise.” Currently, he is the Lead Principal Investigator of two Comprehensive Cancer Research Partnership between UAB Comprehensive Cancer Center and Tuskegee University, Tuskegee, AL and Morehouse School of Medicine, Atlanta, GA (U54); and Alabama State University, Montgomery, AL (P20) to Reduce Cancer Health Disparities by implementing innovative, multi-disciplinary, collaborative, population-based cancer control and prevention research and has contributed to education, training, and community outreach activities. These two programs are funded by the National Cancer Institute of the National Institute of Health.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Meta-analysis of the robustness of COVID-19 diagnostic kit performance during the early pandemicBMJ Open.  12:e053912. 2022
    2022 Understanding the significance of biological clock and its impact on cancer incidenceCancer Letters.  527:80-94. 2022
    2022 GLI1-targeting drugs induce replication stress and homologous recombination deficiency and synergize with PARP-targeted therapies in triple negative breast cancer cells 2022
    2021 Immunophenotype-associated gene signature in ductal breast tumors varies by receptor subtype, but the expression of individual signature genes remains consistentCancer Medicine.  10:5712-5720. 2021
    2021 Age-dependent heterogeneity of lymph node metastases and survival in breast cancer: A population-based study 2021
    2021 Positive Retrospective SARS-CoV-2 Testing in a Case of Acute Respiratory Distress Syndrome of Unknown Etiology. 2021
    2020 A quantitative centrosomal amplification score predicts local recurrence of ductal carcinoma in situClinical Cancer Research.  26:2898-2907. 2020
    2020 Identification of distinct heterogenic subtypes and molecular signatures associated with african ancestry in triple negative breast cancer using quantified genetic ancestry models in admixed race populationsCancers.  12. 2020
    2020 PAICS, a purine nucleotide metabolic enzyme, is involved in tumor growth and the metastasis of colorectal cancerCancers.  12. 2020
    2019 Inclusiveness and ethical considerations for observational, translational, and clinical cancer health disparity researchCancer.  125:4452-4461. 2019
    2019 Disparities in clinical outcomes across age, sex and race among patients with pancreatic adenocarcinoma: a single center experienceAnnals of Oncology.  30:iv64. 2019
    2019 Efficacy and tolerability of the combination of Liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic cancers: post-approval clinic experienceAnnals of Oncology.  30:iv74. 2019
    2019 Neoadjuvant modified FOLFIRINOX or gemcitabine-nab paclitaxel followed by stereotactic body radiotherapy for patients with locally advanced pancreatic cancerAnnals of Oncology.  30:iv67. 2019
    2019 Prognostic role of androgen receptor in triple negative breast cancer: A multi-institutional studyCancers.  11. 2019
    2019 Stereotactic body radiotherapy in locally advanced pancreatic adenocarcinoma: A single institution experienceAnnals of Oncology.  30:iv89. 2019
    2018 Detection of BRAF V600E mutations with next-generation sequencing in infarcted thyroid carcinomas after fine-needle aspirationAmerican Journal of Clinical Pathology.  150:177-185. 2018
    2018 Single molecule mtDNA fiber FISH for analyzing numtogenesisAnalytical Biochemistry.  552:45-49. 2018
    2018 Prostate cancer health disparities: An immuno-biological perspectiveCancer Letters.  414:153-165. 2018
    2017 Bromoethylindole (BEI-9) redirects NF-κB signaling induced by camptothecin and TNFα to promote cell death in colon cancer cells 2017
    2016 Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and PerspectiveCurrent Colorectal Cancer Reports.  12:332-344. 2016
    2016 A comparison of 12-gene colon cancer assay gene expression in African American and Caucasian patients with stage II colon cancerBMC Cancer.  16. 2016
    2016 Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancerCancer Letters.  374:304-314. 2016
    2016 Targeting Hsp70: A possible therapy for cancerCancer Letters.  374:156-166. 2016
    2015 Antitumor activity of melinjo (Gnetum gnemon L.) seed extract in human and murine tumor models in vitro and in acolon-26 tumor-bearing mouse model in vivoCancer Medicine.  4:1767-1780. 2015
    2015 IND-2, a pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinoline derivative, circumvents multi-drug resistance and causes apoptosis in colon cancer cellsBioorganic and Medicinal Chemistry.  23:602-611. 2015
    2014 Variable NF-κB pathway responses in colon cancer cells treated with chemotherapeutic drugsBMC Cancer.  14. 2014
    2013 Clinical implications of microRNAs in cancer 2013
    2013 Post-transcriptional processing of genetic information and its relation to cancer 2013
    2013 The prognostic value of MicroRNAs varies with patient race/ethnicity and stage of colorectal cancerClinical Cancer Research.  19:3955-3965. 2013
    2013 Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53 2013
    2012 Characterization of the colorectal cancer-associated enhancer MYC-335 at 8q24: The role of rs67491583Cancer Genetics.  205:25-33. 2012
    2012 Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells 2012
    2011 Development and progression of colorectal neoplasiaCancer Biomarkers.  9:235-265. 2011
    2011 The biology of incipient, pre-invasive or intraepithelial neoplasiaCancer Biomarkers.  9:21-39. 2011
    2011 Translational pathology of neoplasiaCancer Biomarkers.  9:7-20. 2011
    2010 MiRNAs as biomarkers for management of patients with colorectal cancerBiomarkers in Medicine.  4:761-770. 2010
    2010 Prognostic value of mucin 4 expression in colorectal adenocarcinomasCancer.  116:3577-3586. 2010
    2010 Smad signaling is required to maintain epigenetic silencing during breast cancer progressionCancer Research.  70:968-978. 2010
    2009 Effect of comorbidity and body mass index on the survival of African-American and Caucasian patients with colon cancerCancer.  115:5798-5806. 2009
    2009 Combined effects of formalin fixation and tissue processing on immunorecognition Fixation effects on immunostaining 2009
    2009 Combined effects of formalin fixation and tissue processing on immunorecognition. 2009
    2009 Furthering the evidence-based management of dermatologic effects of EGFR inhibitor therapyCurrent Colorectal Cancer Reports.  5:179-181. 2009
    2009 Prognostic significance of p53 Codon 72 polymorphism differs with race in colorectal adenocarcinomaClinical Cancer Research.  15:2406-2416. 2009
    2009 Immunohistochemical expression of rabphilin -3A-like (Noc2) in normal and tumor tissues of human endocrine pancreas 2009
    2007 The need for review and understanding of SELDI/MALDI mass spectroscopy data prior to analysisCancer Informatics.  1:86-97. 2007
    2007 African-American and Caucasian disparities in colorectal cancer mortality and survival by data source: An epidemiologic reviewCancer Biomarkers.  3:301-313. 2007
    2007 Comparison of predicted probabilities of proportional hazards regression and linear discriminant analysis methods using a colorectal cancer molecular biomarker databaseCancer Informatics.  3:115-122. 2007
    2007 Predicting 5-year survival of colorectal carcinoma patients using data mining methods.AMIA ... Annual Symposium proceedings / AMIA Symposium. AMIA Symposium.  907. 2007
    2006 Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates.American Journal of Clinical Pathology.  126:572-579. 2006
    2006 Mucinous expression in benign and neoplastic glandular lesions of the uterine cervixArchives of Pathology and Laboratory Medicine.  130:1510-1515. 2006
    2006 Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates: A translational research applicationAmerican Journal of Clinical Pathology.  126:572-579. 2006
    2006 Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations 2006
    2005 High-grade tumor differentiation is an indicator of poor prognosis in African Americans with colonic adenocarcinomasCancer.  103:2163-2170. 2005
    2005 Recurrence and survival predictive value of phenotypic expression of Bcl-2 varies with tumor stage of colorectal adenocarcinomaCancer Biomarkers.  1:241-250. 2005
    2004 Postsurgical disparity in survival between African Americans and Caucasians with colonic adenocarcinoma [2] (multiple letters)Cancer.  101:2899. 2004
    2004 Postsurgical disparity in survival between African Americans and Caucasians with colonic adenocarcinomaCancer.  101:66-76. 2004
    2004 Prognostic Significance of p27kip-1 Expression in Colorectal Adenocarcinomas Is Associated with Tumor StageClinical Cancer Research.  10:1743-1752. 2004
    2003 MUC1 and MUC2 Expression in Pancreatic Ductal Carcinoma Obtained by Fine-Needle AspirationCancer.  99:365-371. 2003
    2003 The efficacy of 9-Cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: Results of a randomized double-blind clinical trialCancer Epidemiology, Biomarkers and Prevention.  12:114-119. 2003
    2003 Nuclear accumulation of p53 is a potential marker for the development of squamous cell lung cancer in smokersChest.  123:181-186. 2003
    2002 Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lungClinical Cancer Research.  8:734-744. 2002
    2002 Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: A sensitive method for assessing 5-fluorocytosine toxicity in VitroAnalytical Biochemistry.  301:189-199. 2002
    2001 Altered subcellular localization of Suppressin, a novel inhibitor of cell-cycle entry, is an independent prognostic factor in colorectal adenocarcinomasClinical Cancer Research.  7:3495-3503. 2001
    2001 Molecular characterization of colorectal neoplasia in translational researchArchives of Pathology and Laboratory Medicine.  125:91-98. 2001
    2000 Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomasClinical Cancer Research.  6:4017-4025. 2000
    2000 Immunohistochemical evaluation of global DNA methylation: Comparison with in vitro radiolabeled methyl incorporation assay 2000
    1998 Nuclear accumulation of p53 in colorectal adenocarcinoma prognostic importance differs with race and location of the tumorCancer.  83:2456-2467. 1998
    1997 The use of biomarker expression to characterize neoplastic processes 1997
    Comparative transcriptome analyses reveal genes associated with SARS-CoV-2 infection of human lung epithelial cells

    Chapter

    Year Title Altmetric
    2012 Development and progression of colorectal neoplasia.  235-265. 2012

    Research Overview

  • Translational research in grastrointestinal malignancies and breast cancer - Dr. Manne’s present efforts are focused on population-based translational research for human neoplasias, with emphasis on colorectal and breast cancers. His laboratory, with projects funded by the National Cancer Institute and the Susan G. Komen Foundation, is evaluating molecular markers to identify aggressive phenotypic features of tumors to predict the efficacy of chemotherapeutic regimens and to assess clinical outcomes. Dr. Manne’s research and collaborative groups include experts in the fields of molecular biology, clinical oncology, pathology, epidemiology, statistics, and bioinformatics. For evaluating the clinical utility of genetic and phenotypic abnormalities in colorectal cancer, his group has developed strategies demonstrating that the utility of molecular biomarkers varies according to the anatomic location of tumors within the colorectum and with tumor stage, race/ethnicity, age, and gender. To validate the clinical utility of genetic and phenotypic markers, Dr. Manne’s laboratory is evaluating hundreds of colorectal cancer samples derived from African American and non-Hispanic Caucasian ethnic/racial backgrounds and collected from different institutions. Established molecular markers with be merged with other epidemiological, environmental, and socio-economic features to find the basis for racial disparities in colorectal and breast malignancies. Results from approaches involving biomarker discovery and bioinformatics will aid in developing predictive models specific for individual patients. The research interests of Dr. Manne also include use of genomics and proteomics for identification of early markers of cancers, specifically, identification of molecular signatures of benign colonic epithelium, which is at risk of developing colorectal neoplasias, and of other pre-malignant lesions. These studies will aid in the evaluation of molecular and pathologic characteristics of specimens and in the development of assays that relate to early detection, diagnosis, prognosis, and treatment of cancers.

    Keywords - Colorectal Cancer, Breast Cancer, Molecular Biomarkers, Racial/Ethnic Disparities, Cancer Control & Prevention
  • Principal Investigator On

  • 1/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership  awarded by National Cancer Institute/NIH/DHHS
  • 1/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership - Administrative Core  awarded by National Cancer Institute/NIH/DHHS
  • 1/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership - Pilot Project #1  awarded by National Cancer Institute/NIH/DHHS
  • 3/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership - Research Projects  awarded by National Cancer Institute/NIH/DHHS
  • 3/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama at Birmingham O'Neal Comprehensive Cancer Center Partnership - Admin Core  awarded by National Cancer Institute/NIH/DHHS
  • 3/3 Morehouse School of Medicine/Tuskegee University/University of Alabama Cancer Center Partnership  awarded by National Cancer Institute/NIH/DHHS
  • 3/3 Morehouse School of Medicine/Tuskegee University/University of Alabama at Birmingham O'Neal Comprehensive Cancer Center Partnership  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Tissue Procurement Shared Facility  awarded by National Cancer Institute/NIH/DHHS
  • EDRN Project-Prognostic Markers in Lynch Syndrome Colorectal Cancers  awarded by CREIGHTON UNIVERSITY
  • Effects of NefM1 Peptide on Primary and Metastatic Colorectal Cancer Xenografts  awarded by Michigan State University
  • Hedgehog/Gli1- Targeted Therapies to Overcome Ovarian Cancer Chemoresistance and Disease Recurrence  awarded by TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER
  • Morehouse School of Medicine/Tuskegee University/University of Alabama Cancer Center Partnership  awarded by National Cancer Institute/NIH/DHHS
  • Morehouse School of Medicine/Tuskegee University/University of Alabama Cancer Center Partnership: (Admin Supplement) to Support Development of PDX at UAB CCC  awarded by National Cancer Institute/NIH/DHHS
  • Morehouse School of Medicine/Tuskegee University/University of Alabama Cancer Center Partnership: Administrative Core  awarded by National Cancer Institute/NIH/DHHS
  • Predictive Molecular Markers of Colorectal Cancer  awarded by National Cancer Institute/NIH/DHHS
  • Safer Approaches to Colorectal Cancer Chemoprevention  awarded by BOARD OF TRUSTEES OF THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER
  • Education And Training

  • Doctor of Philosophy in Zoology / Animal Biology, Osmania University 1987
  • Full Name

  • Upender Manne